Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | NLRP1 | Q9C000 | 1/20 | 0.47 |
| ▸ | ITGA1 | P56199 | 4/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.44 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | PPARG | P37231 | 6/20 | 0.41 |
| ▸ | EDNRB | P24530 | 1/20 | 0.40 |
| ▸ | EDNRA | P25101 | 1/20 | 0.40 |
| ▸ | CDK1 | P06493 | 1/20 | 0.39 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.39 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2171063 | 0.80 | MAPT (0.44) | MAPTMEN1LMNAKMT2ATSHR | |
| SCHEMBL2169630 | 0.78 | CES1 (0.51) | MAPTMEN1LMNAALOX12KMT2A | |
| SCHEMBL14018765 | 0.73 | MAPT (0.66) | MAPTMEN1LMNAALOX12KMT2A | |
| SCHEMBL2171249 | 0.70 | TRIM24 (0.49) | MAPTMEN1LMNAKMT2AHTT | |
| SCHEMBL3268657 | 0.68 | MAPT (0.61) | MAPTMEN1LMNAALOX12KMT2A | |
| SCHEMBL2029062 | 0.68 | ITGA1 (0.68) | MAPTMEN1LMNAALOX12KMT2A | |
| SCHEMBL16325537 | 0.68 | CDK1 (0.65) | MAPTMEN1LMNAALOX12KMT2A | |
| SCHEMBL94831 | 0.67 | MAPT (0.63) | MAPTMEN1LMNAALOX12KMT2A | |
| SCHEMBL14018772 | 0.67 | MAPT (0.63) | MAPTMEN1LMNAALOX12KMT2A | |
| SCHEMBL28121241 | 0.67 | MAPT (0.63) | MAPTMEN1LMNAALOX12KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2346847-B1 | ARYL SULFONAMIDE AMINE COMPOUNDS AND THEIR USE AS 5-HT6 LIGANDS | SUVEN LIFE SCIENCES LTD (IN) | 2013-05-15 | — | — | EP | claimed |
| US-20120129816-A1 | ARYL SULFONAMIDE AMINE COMPOUNDS AND THEIR USE AS 5-HT6 LIGANDS | SUVEN LIFE SCIENCES LIMITED (IN) | 2012-05-24 | — | — | US | claimed |
| EP-2346847-A1 | ARYL SULFONAMIDE AMINE COMPOUNDS AND THEIR USE AS 5-HT6 LIGANDS | Suven Life Sciences Limited (IN) | 2011-07-27 | — | — | EP | claimed |
| WO-2010032258-A1 | ARYL SULFONAMIDE AMINE COMPOUNDS AND THEIR USE AS 5-HT6 LIGANDS | SUVEN LIFE SCIENCES LIMITED (IN) | 2010-03-25 | — | — | WO | claimed |
| EP-2346847-B1 | ARYL SULFONAMIDE AMINE COMPOUNDS AND THEIR USE AS 5-HT6 LIGANDS | SUVEN LIFE SCIENCES LTD (IN) | 2013-05-15 | — | — | EP | disclosed |
| US-8404720-B2 | Aryl sulfonamide amine compounds and their use as 5-HT6 ligands | SUVEN LIFE SCIENCES LIMITED (IN) | 2013-03-26 | — | — | US | disclosed |
| US-20120129816-A1 | ARYL SULFONAMIDE AMINE COMPOUNDS AND THEIR USE AS 5-HT6 LIGANDS | SUVEN LIFE SCIENCES LIMITED (IN) | 2012-05-24 | — | — | US | disclosed |
| EP-2346847-A1 | ARYL SULFONAMIDE AMINE COMPOUNDS AND THEIR USE AS 5-HT6 LIGANDS | Suven Life Sciences Limited (IN) | 2011-07-27 | — | — | EP | disclosed |
| WO-2010032258-A1 | ARYL SULFONAMIDE AMINE COMPOUNDS AND THEIR USE AS 5-HT6 LIGANDS | SUVEN LIFE SCIENCES LIMITED (IN) | 2010-03-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120129816-A1 | ARYL SULFONAMIDE AMINE COMPOUNDS AND THEIR USE AS 5-HT6 LIGANDS | HTR6, HTR1A, HTR5A | MAPT 69/4885MEN1 2669/4885LMNA 3840/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.